Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15814881 | 0.85 | IGF1R (0.48) | IGF1RPLK4PAK4INSR | |
| SCHEMBL17397443 | 0.85 | IGF1R (0.67) | IGF1RPLK4PAK4INSR | |
| SCHEMBL15815782 | 0.82 | IGF1R (0.67) | IGF1RINSR | |
| SCHEMBL4908609 | 0.82 | IGF1R (0.62) | IGF1RINSRAURKA | |
| SCHEMBL18836699 | 0.81 | IGF1R (0.63) | IGF1RINSR | |
| SCHEMBL802154 | 0.81 | IGF1R (0.57) | IGF1RPLK4PAK4MEN1HTT | |
| SCHEMBL12430741 | 0.80 | IGF1R (0.54) | IGF1RPLK4PAK4MEN1HTT | |
| SCHEMBL16540730 | 0.80 | IGF1R (0.64) | IGF1RINSR | |
| SCHEMBL30353169 | 0.78 | IGF1R (0.57) | IGF1RPLK4PAK4MEN1HTT | |
| SCHEMBL801533 | 0.78 | IGF1R (0.71) | IGF1RAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499519-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9422267-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, FGFR3, FGFR1 | IGF1R 1/4885PLK4 524/4885PAK4 956/4885 |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, IPMK, IP6K2 | IGF1R 1/4885PLK4 692/4885PAK4 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.